Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators.
A full genome search in multiple sclerosis.
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Keystone Symposium: Advances in the Knowledge and Treatment of Autoimmunity
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Alemtuzumab and multiple sclerosis: therapeutic application.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Impact of MS during the critical window of brain development.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
The immunopathology of multiple sclerosis: an overview.
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Drug Safety Labeling Changes
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
A genetic screen identifies genes essential for development of myelinated axons in zebrafish.

Pages